Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

NCT03687242 is registered in ClinicalTrials.gov with Spruce Biosciences as lead sponsor.

NCT NCT03687242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03687242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Lead sponsor
Spruce Biosciences
Phase
Phase 2
Overall status
Completed
Start date
September 6, 2018
Completion date
August 9, 2019
Enrollment
11 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cah - 21-hydroxylase deficiency, cah - congenital adrenal hyperplasia, congenital adrenal hyperplasia